Results 191 to 200 of about 89,572 (287)

Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience. [PDF]

EJNMMI Res
Ebert N, Rosar F, Burgard C, Bartholomä M, Maus S, Hein C, Blickle A, Ezziddin S, Khreish F.   +8 more
europepmc   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, Volume 16, Issue 6, Page 1197-1212, June 2026.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Ultrasmall Platinum Nanoparticles for Radiation‐Enhanced Cancer Therapy

Advanced Functional Materials, Volume 36, Issue 45, 5 June 2026.
This work proposes a nanomedicine‐based strategy to enhance X‐ray radiotherapy for cancer treatment. Ultrasmall Pt‐NPs exhibit catalase‐like activity that may contribute to modulation of the tumor microenvironment and amplify interactions between radiation and biological matter, leading to increased DNA damage.
Miguel Encinas‐Gimenez, Jose I. Garcia‐Peiro, Jose L. Hueso, Eduardo Caleiras, Laura Notario, Felipe Hornos, Pilar Martin‐Duque, Antonio De la Vieja, Jesus Santamaria   +8 more
wiley   +1 more source

Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis. [PDF]

Explor Target Antitumor Ther
Rath S, Sajjad F, Rehman KA, Bacha Z, Saleh AO, Hayat U, Alam U, Ullah W, Brohi F, Ahmad O, Khan M, Lal A.   +11 more
europepmc   +1 more source

Functional Precision Oncology Approach Using Nanoliter Droplet Array for Drug Sensitivity Testing in Lung Cancer

Advanced Healthcare Materials, Volume 15, Issue 24, 25 June 2026.
A miniaturized drug sensitivity and resistance testing (DSRT) workflow based on the Droplet Microarray (DMA) platform enables functional drug testing using minimal patient‐derived tumor material. By screening nanoliter‐scale droplets containing as few as 300 cells, this approach generates reproducible and tumor‐specific drug response profiles ...
Maryam Salarian, Vicky L. Schiling, Thomas Muley, Michael Allgäuer, Florian Eichhorn, Michael Meister, Marc A. Schneider, Anna A. Popova   +7 more
wiley   +1 more source

Durable Disease Control in Disseminated Primary Splenic Leiomyosarcoma Treated With Sequential Gemcitabine-Docetaxel and Pazopanib Therapy: A Case Report. [PDF]

Cureus
Kurbanova S, Sharobiddinov B, Abdusattorova O, Abdusattorov R.   +3 more
europepmc   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial. [PDF]

Signal Transduct Target Ther
Wu J, Li X, Gu C, Hua L, Liu R, Li J, Qiu M, Guo J, Dong H, Ji Z, Xie L, Zhu S, Zhang X, Chen P, Jiang S, Sun Z, Xu D, Chen H, Shi B, Wang Y, Pu J, Perabo F, Chen Y, Ye D.   +23 more
europepmc   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Directly comparing randomized and real-world controls in adjuvant breast cancer. [PDF]

J Comp Eff Res
Walker B, Boyd M, Silver M, Shi J, Bulsara P, Balanchivadze N, Robert NJ.   +6 more
europepmc   +1 more source